Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
Rhea-AI Summary
Aquestive Therapeutics (NASDAQ:AQST) said its management team will attend four investor conferences in March, including TD Cowen, Leerink Partners, Citizens Life Sciences, and Barclays.
Presentations, a Leerink fireside chat, and 1x1 meetings are scheduled; webcasts and 30-day replays will be posted on the company's Investors "Events and Presentation" page.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: in the watchlist, ORGO is up 2.81%, AKBA up 2.48%, while ESPR is down 1.79% and EOLS is down 0.23%. Momentum scanner peers are split, with AKBA up 1.61%, ETON up 2.52%, and SIGA down 0.74%, pointing to stock-specific rather than broad sector action.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Investor conference | Neutral | +0.5% | Participation in Oppenheimer virtual healthcare conference with webcast and 1x1s. |
| Feb 20 | Clinical data update | Positive | +0.4% | New Anaphylm clinical data to be presented at AAAAI meeting showing relevant exposure. |
| Feb 18 | Management change | Positive | -1.3% | Appointment of distinguished allergist as Chief Medical Officer to support Anaphylm NDA. |
| Feb 02 | Regulatory setback | Negative | +39.0% | FDA Complete Response Letter for Anaphylm focusing on packaging and PK study needs. |
| Jan 09 | Regulatory update | Negative | -37.0% | FDA identified NDA deficiencies that could delay Anaphylm approval ahead of PDUFA date. |
News and clinical updates have produced mixed reactions, with some regulatory setbacks triggering sharp, sometimes counterintuitive moves.
Over the past few months, Aquestive has alternated between operational updates and major regulatory developments around Anaphylm. A January update on FDA-identified NDA deficiencies and cash of $120 million was followed by a Complete Response Letter on Jan 30, 2026, which unexpectedly saw a 38.98% gain. Subsequent leadership changes and clinical data presentations on Anaphylm had modest price impacts. Today’s March conference participation fits the pattern of routine investor-relations outreach alongside ongoing regulatory and clinical work.
Market Pulse Summary
This announcement outlines a concentrated March schedule of four investor conferences, increasing management’s opportunities for 1x1 meetings and visibility through webcast presentations, with replays available for 30 days. In context, the company recently navigated FDA deficiencies and a Complete Response Letter for Anaphylm while also presenting new clinical data and adjusting its leadership team. Investors may watch how upcoming regulatory steps, clinical updates, and subsequent communications at these events shape the evolving narrative around Anaphylm and the broader pipeline.
AI-generated analysis. Not financial advice.
WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in March as follows:
- TD Cowen 46th Annual Health Care Conference: Management will be available for 1x1 meetings on Tuesday, March 3rd
- Leerink Partners Global Healthcare Conference 2026: fireside chat to take place on Monday, March 9th at 10:40am ET; management will also be available for 1x1 meetings
- Citizens Life Sciences Conference: presentation to take place on Tuesday, March 10th at 8:25am ET; management will also be available for 1x1 meetings
- Barclays 28th Annual Global Healthcare Conference: Management will be available for 1x1 meetings on Wednesday, March 11th
A webcast of the presentations at the conferences will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.
About Aquestive Therapeutics, Inc.
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. The worldwide leader in delivering trusted, quality medications on oral film, Aquestive operates as both a developer of its own proprietary products and a Contract Development and Manufacturing Organization (CDMO) for licensees, with its headquarters in New Jersey and U.S.-based manufacturing facilities in Indiana. The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents using proprietary, best-in-class technologies like PharmFilm®. Aquestive's AdrenaVerse™ platform contains a library of more than 20 epinephrine prodrugs enabling the pursuit of various potential allergy and dermatological indications. The Company is advancing Anaphylm™ (dibutepinephrine) sublingual film for the treatment of severe allergic reactions, including anaphylaxis, and AQST-108 (epinephrine prodrug) topical gel for various potential dermatological conditions, including alopecia areata. For more information, visit Aquestive.com and follow us on LinkedIn.
Forward Looking Statement
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials, including relating to Anaphylm™ (dibutepinephrine) sublingual film, and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.
PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.
Investor Contact:
Brian Korb
astr partners
brian.korb@astrpartners.com
FAQ
When will Aquestive (AQST) present at the TD Cowen 46th Annual Health Care Conference in March 2026?
What is the date and format of Aquestive's (AQST) Leerink Partners Global Healthcare Conference appearance?
When and how will Aquestive (AQST) present at the Citizens Life Sciences Conference in March 2026?
What is Aquestive's (AQST) schedule for the Barclays 28th Annual Global Healthcare Conference in March 2026?
Will Aquestive (AQST) provide webcasts or replays of its March 2026 investor presentations?
How can investors access more information or arrange meetings with Aquestive (AQST) for the March 2026 conferences?
